


STUDIES DIRECTED TOWARD THE TOTAL SYNTHESIS OF TETRONOLIDE 1. AN ENANTIOSELECTIVE SYNTHESIS OF THE OCTAHYDRONAPHTHALENE UNIT

Robert K Boeckman Jr,* Thomas E Barta, and Scott G Nelson

Department of Chemistry
University of Rochester
Rochester, New York 14627

Summary An efficient enantioselective route to the octahydronaphthalene unit present in tetronolide (1), the stereochemically complex aglycone common to the tetrocarcins, a novel group of antitumor substances, is described. The sequence employs the intramolecular Diels-Alder reaction to control the relative stereochemistry present on the trans decalin ring system, and incorporates a masked acylating agent which should permit coupling of the two key fragments 2 and 3 as demonstrated by reaction of pentaene 4 with methanol and a model α -hydroxy ester.


The tetrocarcins comprise a group of antitumor antibiotic agents which share a common aglycone, tetronolide 1.¹ Structurally, tetronolide is related to kijanoid and chlorothricolide, the aglycone units of kijanomycin and chlorothricin, the only other known members of this natural product family.^{2,3} These structurally complex aglycones have been the subject of considerable effort directed toward their preparation, although no total synthesis of a naturally-occurring member of this class has yet been completed.⁴ In accord with our interest in developing stereoselective variants of the intramolecular Diels-Alder cycloaddition, we chose tetronolide to test the scope of this methodology. We conceived a convergent synthetic



strategy (Scheme 1), whose implementation required the preparation, in enantiomerically pure form, and union of two key synthons comprising the octahydronaphthalene 2 and cyclohexene 3 subunits of 1 or precursors thereof. Herein, we describe the development of a suitable route to pentaene 4, an enantiomerically pure precursor of 2.^{5,6}


The advantages of employing a [4+2] cycloaddition to control the relative stereochemistry of centers present on the decalin framework of 2 was recognized early on, and this strategy has been employed by several groups.^{7,8} However, our approach differs significantly in the manner

by which the major fragments will be joined, since in all other studies to date the major subunits are to be joined in a separate step, whereas we envisioned the coupling process in tandem with the intramolecular [4+2] cycloaddition. Thus, the required substrate for construction of **2** becomes pentaene **4**, whose synthesis is outlined below. The requisite pentaene **4** was expected to arise *via* the sequential combination of phosphine oxide **5** and dioxinone phosphonate **6** with an appropriate aldehyde derived from enantiomerically pure, differentially protected triol **7** (Scheme 1).

Scheme 2^a

^aReagents: a) NaH, $p\text{CH}_3\text{OPhCH}_2\text{Cl}$, THF, 25°C, 12h; b) $n\text{BuLi}$, -78°C, THF, 10min then $(\text{CH}_2\text{O})_n$, -78°C → 25°C, 1h; c) LAH, THF, 0°C, 5h; d) NCS/DMS, CH_2Cl_2 , 0°C 0.5h; e) Ph_2PLi , THF, -78°C, 1h then H_2O_2 , 0°C, 5 min.

Preparation of **5** was accomplished by conversion of E-2-methyl-2-pentene-4-yn-1-ol to E, E allylic chloride **8** in 4 steps employing standard methodology (69% overall) as shown in Scheme 2.⁹⁻¹¹ Chloride **8** was then converted to the required phosphine oxide **5** in 50% yield by exposure of **8** to lithio diphenylphosphine and subsequent oxidation with H_2O_2 in CH_2Cl_2 at 0°C. Dioxinone phosphonate **6** was obtained in a single step (Eqn 1) from dioxinone **9**¹² *via* conversion to the lithium enolate with LDA and treatment with diethylchlorophosphite, followed by oxidation *in situ* (H_2O_2 , CH_2Cl_2 , 0°C) to afford a 60% yield of phosphonate **6**.¹³




Construction of the enantiomerically pure triol **7** was initiated from (R)-(-)-methyl 3-hydroxy-2-methylpropionate which was converted in 5 steps using standard methods to aldehyde **10** in 73% overall yield (Scheme 3). Condensation of aldehyde **10** with the sodium anion of ethyl diethylphosphonoacetate afforded the expected E unsaturated ester **11** (97%) which provided allylic alcohol **12** upon reduction with DIBAL-H (95%). The two remaining stereogenic centers were installed *via* 3 step sequence involving catalytic asymmetric epoxidation¹⁴ to afford epoxy alcohol **13** (86%, 88% de), followed by benzylation, and treatment of the protected epoxide with lithium dimethylcuprate in Et_2O at -45°C to afford a mixture (7:1) of diastereomeric alcohols **14** and **15** (86% combined from **13**).¹⁵ Protection of the remaining alcohol as the methoxymethyl ether then furnished a readily separable mixture of the desired triol **7** (86%) and its regioisomer **16** (12%).¹⁶

Assembly of pentaene **4** from the three major subunits **5-7** was also readily accomplished (Scheme 3). Sequential catalytic debenylation of **7** (~100%), Swern oxidation (90%),¹⁷ and condensation of the resulting aldehyde with the lithium anion derived from **5** at -78°C in THF with added HMPA smoothly provided, as a single geometric isomer, the E,E,E triene **17** (86%). Repetition of the deprotection, oxidation, olefination sequence on **17** employing instead fluoride to cleave the silyl ether, and the lithium anion derived from **6** in THF with added HMPA delivered exclusively the required Z,E,E,E pentaene **4** (53% from **17**).¹⁸


With the key pentaene **4** in hand, we were in a position to test whether **4** fulfilled the crucial requirements of the intended tandem coupling/cycloaddition assembly of **2** and **3**: 1) that the thermally generated acyl ketene undergo efficient intermolecular capture by a suitable 3° alcohol (ultimately the required cyclohexene synthon **3**), and 2) that the subsequent cycloaddition proceed with high stereoselectivity creating the correct stereochemical relationships about the octahydronaphthalene ring system.¹⁹

To test the essential feasibility of the coupling/cycloaddition, we first examined thermolysis of **4** at 110°C in the presence of excess methanol (~100 equiv), which afforded the desired decalin **18** in 54% yield along with 5% of uncharacterized diastereomeric cycloadduct(s)

Scheme 3^a

^aReagents a) TBDPSCI, imidazole (2 equiv), 25°C, 5h, b) DIBAL-H (2 equiv), THF, -78°C, 2h, c) TsCl, DMAP, Py, CH₂Cl₂, 25°C, 12h, d) KCN, EtOH-H₂O (1:1), Δ, 10h, e) DIBAL-H, THF, -78°C → 25°C, 1h, f) C₂H₅O₂CCH₂P(O)(OC₂H₅)₂, NaH, THF, -78°C → 25°C, 10h, g) DIBAL-H (2 equiv), THF, -78°C, 2h, h) Ti(OiPr)₄ (catalytic), (-)-DET (catalytic), tBuOOH, CH₂Cl₂, -20°C, 24h, i) NaH, PhCH₂Br, THF, 25°C, 1h, j) (CH₃)₂CuLi (10 equiv), Et₂O, -45°C, 2h, k) CH₃OCH₂Cl, EtN(iPr)₂, THF, 25°C, 12h, l) H₂ (1 atm), Pd/C, EtOH, 25°C, 10h, m) (COCl)₂, DMSO, Et₃N, -78°C, 1h, n) 5, *n*BuLi, THF-HMPA (2:1), -78°C, 1h, o) TBAF, THF, 25°C, 5h, p) 6, *n*BuLi, THF-HMPA (2:1), -78°C, 2h, q) Δ (toluene, 110°C (sealed tube), or xylenes, 130°C (sealed tube))

(Scheme 3) The stereochemistry of **18** was confirmed via 300 and 500 MHz NMR spectroscopy with appropriate decoupling.²⁰ This result is consistent with the expectation that the cyclization would occur nearly exclusively through an endo-chair transition state in which the facial bias would be imparted by the C-3 substituent which preferentially occupies an equatorial orientation in the transition state so as to alleviate a non-bonded interaction with the C-8 proton.^{4c,5,6,21} We have also demonstrated the capture of a model 3° nucleophile in the form of hydroxy ester **19**, which afforded the related decalin **20** (~50%, unoptimized, >20:1 stereoselectivity) upon thermolysis of **4** at 130°C in xylenes in the presence of 1 equiv of **19**.



Our studies have resulted in the development of an enantioselective route to key pentaene synthon **4** and the demonstration of the feasibility of a tandem coupling/cycloaddition methodology for the stereoselective preparation of octahydronaphthalene subunits for **1**. The following communication details our approach to cyclohexene **3**. Application of this methodology to the total synthesis of tetronolide **1** is currently under investigation.

Acknowledgement. We are grateful to the National Cancer Institute of the National Institutes of Health for the award of a research grant (CA-29108) in support of these studies. We thank the Merck Co. for fellowship support awarded to SGN.

References and Notes:

- (1) Tamiki, T.; Kasai, M.; Shirahata, K.; Tomita, F. *J. Antibiotics*. **1982**, *35*, 979.
- (2) Waitz, J. A.; Horan, A. C.; Kalyanpur, M.; Lee, B. K.; Loebenberg, D.; Marquez, J. A.; Miller, G.; Patel, M. G. *J. Antibiotics* **1981**, *34*, 1101.
- (3) Keller-Schierlein, W.; Muntwyler, R.; Pache, W.; Zahner, H. *Helv. Chim. Acta*. **1969**, *52*, 127.
- (4) For leading references to prior work on chlorothricolide and kijanolide see: (a) Marshall, J. A.; Salovich, J. M.; Shearer, B. G. *J. Org. Chem.* **1990**, *55*, 2398. (b) Takeda, K.; Igharashi, Y.; Okazaki, K.; Yoshii, E.; Yamaguchi, K. *J. Org. Chem.* **1990**, *55*, 3431. (c) Roush, W. R.; Kageyama, M.; Riva, R.; Brown, B. B.; Warmus, J. S.; Moriarty, K. J. *J. Org. Chem.* **1991**, *56*, 1192.
- (5) Taken in part from the Ph. D. dissertation of Thomas E. Barta, University of Rochester, 1987.
- (6) Boeckman, Jr., R. K.; Barta, T. E. *J. Org. Chem.* **1985**, *50*, 3421.
- (7) Okumura, K.; Okazaki, K.; Takeda, K.; Yoshii, E. *Tetrahedron Lett.* **1989**, *30*, 2233.
- (8) Ireland, R. E.; Varney, M. D. *J. Org. Chem.* **1986**, *51*, 635.
- (9) Corey, E. J.; Katzenellenbogen, N.; Gilman, N. W.; Roman, A.; Erickson, B. W. *J. Am. Chem. Soc.* **1968**, *90*, 5618.
- (10) Corey, E. J.; Kim, C. U.; Takeda, M. *Tetrahedron Lett.* **1972**, 4339.
- (11) All new substances exhibited satisfactory spectral (NMR, IR, MS) data and microanalytical or high resolution MS data.
- (12) Sato, M.; Ogasawara, H.; Oi, K.; Kato, T. *Chem. Pharm. Bull.* **1983**, *31*, 1896.
- (13) Boeckman, Jr., R. K.; Kamenecka, T. M.; Nelson, S. G.; Pruitt, J. P.; Barta, T. E. *Tetrahedron Lett.*, **1991**, *32*, 0000.
- (14) Hanson, R. M.; Sharpless, K. B. *J. Org. Chem.* **1986**, *51*, 1922.
- (15) Johnson, M. R.; Kishi, Y. *Tetrahedron Lett.* **1979**, 4347.
- (16) The minor isomers incurred in the asymmetric epoxidation and the subsequent epoxide opening were removed at the protected triol stage by chromatography (flash or prep HPLC) to give **7** as a homogeneous substance.
- (17) Mancuso, A. J.; Huang, S. L.; Swern, D. *J. Org. Chem.* **1978**, *43*, 2480.
- (18) The dioxinone phosphonate olefination proceeded in unsatisfactory yields in the absence of HMPA. Yields improved dramatically when a solution of the aldehyde in THF:HMPA(1:1, 1 M overall) was added to the lithiated phosphonate.
- (19) Boeckman, Jr., R. K.; Pruitt, J. R. *J. Am. Chem. Soc.* **1989**, *111*, 8286.
- (20) Decoupling experiments verified that the C₂-C₇ coupling constant for the ring junction protons, and the C₆-C₇ coupling constant for the α -OMOM and adjacent ring junction protons were J=10.3 Hz and J=8.1 Hz respectively, consistent with *trans*-diaxial relationships between these protons and thus with *trans*-fused decalin **18** (Eqn 2).
- (21) Marshall, J. A.; Grote, J.; Audia, J. E. *J. Am. Chem. Soc.* **1987**, *109*, 1186.

(Received in USA 26 April 1991)